277 related articles for article (PubMed ID: 31118571)
1. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
[No Abstract] [Full Text] [Related]
2. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
[TBL] [Abstract][Full Text] [Related]
3. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: daily pantoprazole magnesium 40 mg vs. esomeprazole 40 mg for gastro-oesophageal reflux disease, assessed by endoscopy and symptoms.
Moraes-Filho JP; Pedroso M; Quigley EM;
Aliment Pharmacol Ther; 2014 Jan; 39(1):47-56. PubMed ID: 24299323
[TBL] [Abstract][Full Text] [Related]
6. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
[TBL] [Abstract][Full Text] [Related]
7. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
9. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
Parekh PJ; Oldfield EC; Johnson DA
Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
[TBL] [Abstract][Full Text] [Related]
10. On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study.
Cho JH; Koo JY; Kim KO; Lee SH; Jang BI; Kim TN
Medicine (Baltimore); 2018 Oct; 97(43):e12732. PubMed ID: 30412065
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
Wu MS; Tan SC; Xiong T
Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
[TBL] [Abstract][Full Text] [Related]
12. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
13. Dexlansoprazole and Esomeprazole Do Not Affect Bone Homeostasis in Healthy Postmenopausal Women.
Hansen KE; Nieves JW; Nudurupati S; Metz DC; Perez MC
Gastroenterology; 2019 Mar; 156(4):926-934.e6. PubMed ID: 30445008
[TBL] [Abstract][Full Text] [Related]
14. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis.
Sun J; Yuan YZ; Hou XH; Zou DW; Lu B; Chen MH; Liu F; Wu KC; Zou XP; Li YQ; Zhou LY
World J Gastroenterol; 2015 Jun; 21(22):6965-73. PubMed ID: 26078574
[TBL] [Abstract][Full Text] [Related]
15. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
Gold BD; Pilmer B; Kierkuś J; Hunt B; Perez MC; Gremse D
Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
[TBL] [Abstract][Full Text] [Related]
16. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Placebo-Controlled
Sierra-Arango F; Castaño DM; Forero JD; Pérez-Riveros ED; Ardila Duarte G; Botero ML; Cárdenas A; De la Hoz-Valle J
Can J Gastroenterol Hepatol; 2019; 2019():3926051. PubMed ID: 31929980
[TBL] [Abstract][Full Text] [Related]
18. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.
Tan VP; Wong WM; Cheung TK; Lai KC; Hung IF; Chan P; Pang R; Wong BC
J Gastroenterol; 2011 Jul; 46(7):906-12. PubMed ID: 21538030
[TBL] [Abstract][Full Text] [Related]
19. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
[TBL] [Abstract][Full Text] [Related]
20. GERD assessment including pH metry predicts a high response rate to PPI standard therapy.
Kandulski A; Peitz U; Mönkemüller K; Neumann H; Weigt J; Malfertheiner P
BMC Gastroenterol; 2013 Jan; 13():12. PubMed ID: 23324360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
